Summary
Vertex Pharmaceuticals Inc. (VRTX) announced a significant leadership transition in this 8-K filing dated December 16, 2011. Effective February 1, 2012, Dr. Jeffrey M. Leiden will assume the role of President and Chief Executive Officer, succeeding Matthew W. Emmens. Dr. Leiden, who joined the company on December 14, 2011, will also be appointed Chairman of the Board in May 2012, indicating a strategic leadership shift for the company. This transition is accompanied by detailed employment agreements for Dr. Leiden, outlining his compensation, including a base salary of $1,000,000, a target bonus of 120% of his base salary, and substantial equity awards. These equity awards include stock options and restricted stock grants, with specific vesting schedules and performance-based components. The filing also details severance provisions for Dr. Leiden under various termination scenarios, including a change of control, and outlines Matthew W. Emmens' transition to Executive Chairman before his retirement in May 2012, with no special severance for his transition.
Key Highlights
- 1Dr. Jeffrey M. Leiden appointed President and CEO effective February 1, 2012.
- 2Dr. Leiden will also become Chairman of the Board in May 2012, succeeding Matthew W. Emmens.
- 3Matthew W. Emmens will transition to Executive Chairman and retire in May 2012.
- 4Dr. Leiden's employment agreement includes an initial base salary of $1,000,000 and a target annual bonus of 120% of base salary.
- 5Dr. Leiden received significant equity awards, including stock options and restricted stock grants with time-based and performance-based vesting.
- 6The filing details severance packages for Dr. Leiden under various termination conditions, including change of control.
- 7Mr. Emmens will not receive severance pay or accelerated equity vesting for his transition or retirement.